Analysis Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS)
5/31/2024
Analysis of Recordati Industria Chimica e Farmaceutica S.p.A. (0KBS)
Recordati Industria Chimica e Farmaceutica S.p.A. is a pharmaceutical company based in Italy. Looking at the recent data provided, we can see that the stock symbol '0KBS' has been experiencing some fluctuations in its price, with the price closing at 48.145 on the most recent day.Key indicators such as the Relative Strength Index (RSI), Moving Average Convergence Divergence (MACD), and Moving Averages (MA) can provide insights into the stock's performance.
The RSI indicator is currently at 39.56, indicating that the stock is neither overbought nor oversold. The MACD indicator is negative at -0.67, with the MACD line below the signal line, suggesting a bearish trend. The Moving Averages (MA) show that the stock is below the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA), indicating a downward trend.
Overall, based on the indicators and recent price movements, it seems that the stock of Recordati Industria Chimica e Farmaceutica S.p.A. may be facing some selling pressure. Investors should closely monitor the stock's performance and consider other factors before making any investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions about the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.6%.
2. Next Quarter: The estimated growth rate for the next quarter is 4.8%.
3. Current Year: The estimated growth rate for the current year is 7.5%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 11%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the near term compared to the historical performance. However, the company is still projected to experience double-digit growth over the next 5 years according to analyst consensus.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions regarding the future price of the security, with the low end at $164, the high end at $250, and the average forecast at $202.26. The current price of the security is $191.57, which is below the median and average forecast, indicating that there is potential for growth according to the analysts' predictions.
Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous results, ending on February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at this time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong operating cash flow and levered free cash flow, with a positive current ratio. The profit margin and operating margin are also healthy, indicating efficient operations. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 31, 2024. The company shows good returns on assets and equity.
Looking at stock statistics, the company has a low short ratio and a significant percentage of shares held by institutions. The stock has a beta of 1.264 and has experienced a moderate change in its fifty-two week range.
Valuation metrics show a relatively high PEG ratio and price-to-book ratio. The company's market capitalization and enterprise value are substantial, with moderate price-to-sales and enterprise-to-EBITDA ratios.
The stock price summary includes moving averages, fifty-two week high and low prices, and beta.
Lastly, dividends and splits information shows the company's dividend dates, payout ratios, and dividend yields. The company has had a recent stock split and offers a forward annual dividend rate.
Income statement 💸
Here are the revenue figures for the company over the past four fiscal years:1. Fiscal Year 2020: Sales of $274,515,000,000
2. Fiscal Year 2021: Sales of $365,817,000,000
3. Fiscal Year 2022: Sales of $394,328,000,000
4. Fiscal Year 2023: Sales of $383,285,000,000
From the data, we can observe the following trends:
- There was a steady increase in sales from 2020 to 2022, with a slight decrease in 2023.
- The company experienced significant growth in revenue between 2020 and 2022, indicating positive performance.
- Despite a slight dip in sales in 2023, the revenue figures remain relatively high compared to the base year of 2020.
Overall, the company has shown a positive revenue trend over the past four fiscal years, with substantial growth up to 2022 and a slight decline in 2023.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have shown an increasing trend, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has shown an increasing trend, with the highest value in 2018 at $107,147,000,000.
6. The company has been relying more on non-current assets to finance its operations, as seen in the increasing trend of non-current assets compared to current assets.
7. The company has been able to maintain a positive shareholders' equity throughout the years, indicating a healthy financial position.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show a pattern of common stock repurchase, issuance of long-term debt, and payment of dividends.
6. Investing activities include the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, with a focus on operational performance and strategic investments.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average EPS estimate is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a growth trajectory from the EPS of $6.10 in the current year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, showing a trend of expected growth in both the short term and the long term.
MACD of 0KBS
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
